Good point, but the burn may be much greater, that is likely. The chart was due for a pullback, we may in fact have more retracing to go, as I see it. I sold 20% of my position this morning at 2.51. Not been a happy place in 2014. Took off most of my early buys so I could offset some gains from earlier in the year on some of my better trades.
And along with the increase in share value, we will see increased volatility like today, low of 1.19 and high of 1.25. I added 7,500 shares today, didn't catch the lows but it will all look cheap when this stock reaches fair value around $4.50 or more as trials progress.
Today's short volume was 15% or 121,252 shares = Nov 4th
Friday's short volume was 19% or 225,492 shares
Thursday's sh volume was 36% or 781,636 shares
Wedsday's sh volume was 20% or 577,747 shares = Oct 29th
Those here talking about a short squeeze and offering congratulations to each other seem premature. It offers false hopes in the face of what continues to happen here, more shorting, no covering. I am long 5,000 shares, and most of my shares were purchased into the run-up, now I find myself back holding a bag. I recognize this is part of the short term process when one is accumulating, but my point is let's not get ahead of ourselves. We haven't choked anyone, the shorts are still very much figuring into the action of this stock. We have effectively been giving back our gains, courtesy of the market dynamics in play here. Longs, be vigilant and do not overpay for your shares by getting too excited in here. There will be many buying opportunities ahead, always prepare for consolidation and lower pricing after strong days.
They have decided not to go it alone with QST? Sorry, this may be common knowledge, if so sorry for asking clarification. They were so smugly insistent on doing Otrexup in-house, which was in retrospect, risky and mistaken in my view.
Looks like you dropped one of your stocks Hofno, VICL. Hmmm...after reading your post there, seemed like you were very bullish. Seems safer to me than oral testosterone.
Using your lead post, I found this article dated 12 January 2010, which may help bring others along in your knowledge. I hadn't read about this before.
Published 12 January 2010
Vical has announced that its licensee, AnGes, has received FDA approval for its Special Protocol Assessment (SPA) agreement for a phase 3 clinical trial of its Collategene angiogenesis product, for patients with advanced peripheral arterial disease (PAD). The study will be multinational, randomized and placebo-controlled with a target population of 560 patients.
The phase 3 trial will enroll no option as well as poor option patients with chronic and severe ischemia of the lower limb. No option patients are those unable to receive an endovascular intervention or surgical bypass procedure due to inflow, conduit or outflow reasons or due to a severe and irreversible co-morbidity, where surgery is contraindicated.
Poor option patients are those unable to receive an endovascular intervention and at high risk for bypass surgery due to their vascular anatomy or severe co-morbid disease. Inclusion of poor option patients will open the clinical trial to at least three to four times as many target patients, compared to other trials within the industry which only include no option patients.
Collategene uses Vical's patented DNA technology to deliver a gene encoding hepatocyte growth factor (HGF), a human protein that causes growth of blood vessels when injected in areas of restricted blood flow. In March 2008, AnGes submitted a New Drug Application (NDA) for Collategene to the Japanese Ministry of Health, Labor and Welfare for treatment of CLI. The submission is under review.
AnGes has designed the new phase 3 trial to pursue approvals of Collategene in the US, Canada, Europe, Latin America and other markets beyond Japan.
Yes, that was before the FDA approval, before SNY partnership, doesn't add up does it? We are conducting a 40% off sale, but the product has worldwide marketing in place by a highly trained sales force, is practically guaranteed to sell all that can be produced, our future cash flow is assured, with a safety net covering our expenses. It's de-risked in my view.
After I posted this the stock went further on sale by .28 in what appears to be a sector rotation of institutional money or funds leaving biotech for industrial stocks. My whole portfolio was slammed. One day in a stock, but not a good day. Looking out 6-12 months, all of us will be happy we got in now.
You have soiled your credibility, it is absurd to publicly predict stock moves and very foolish to guarantee your prediction. I suggest you refrain from this type of setup in the future unless you want to be ignored.
Give it up serial pumper...your posting sets up wild expectations that end in disappointment and premature dismay. Better you don't post at all, we would then have more clarity. You have soiled your credibility and hurt investor expectations. Ignore!